Infertility
Conditions
Interventions
Investigational Group:Aqueous progesterone injection II, 25 mg, subcutaneous injection (SC), twice daily (bid)
combined with oral dydrogesterone, 10 mg, twice daily (bid).
Control Group:Progesterone vaginal gel 90 mg vaginally once daily, combined with dydrogesterone 20 mg orally twice daily.
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to 42 Years
Inclusion criteria
Inclusion criteria: 1.Able to communicate well with researchers, understand and follow trial requirements, voluntarily participate, and understand and sign the informed consent form; 2.Women aged 20 to 42 years who are married when signing the ICF; 3.Body mass index (BMI) between 18 kg/m2 and less than 30 kg/m^2; 4.Using HRT-FET treatment, with endometrial thickness >=8mm after at least 10 days of estrogen use; 5.This cycle is the first frozen embryo transfer after egg retrieval, with at least 2-3 high-quality embryos or 1-2 blastocysts available for transfer.
Exclusion criteria
Exclusion criteria: 1. Recurrent miscarriage: Experiencing two or more consecutive losses of embryos or fetuses before 28 weeks of pregnancy, including consecutive biochemical pregnancies. 2. Repeated implantation failure: Defined as failing to achieve a clinical pregnancy after three or more embryo transfers, or after transferring 4-6 high-quality cleavage-stage embryos or 3 or more high-quality blastocysts (including fresh or frozen cycles). 3. Reproductive system diseases that affect pregnancy outcomes (any of the following): (1) Acute reproductive system infection; (2) Abnormal vaginal bleeding under investigation; (3) Severe uterine malformations or significant intrauterine lesions affecting embryo implantation (untreated); (4) Large uterine fibroids (diameter >4cm), etc.; 4. Allergy to active ingredients or excipients in progesterone drugs, or a history of related allergies, or clear contraindications to medication use; 5. Participation in other interventional clinical trials that may interfere; 6. Other situations where the researcher deems the participant unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ongoing pregnancy rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| clinical pregnancy; | — |
Countries
China
Contacts
Public ContactYang Rui
Peking University Third Hospital
Outcome results
None listed